CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 24,800 shares, a growth of 13.8% from the July 15th total of 21,800 shares. Based on an average daily trading volume, of 40,100 shares, the short-interest ratio is currently 0.6 days. Currently, 0.6% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CALC shares. Oppenheimer upped their target price on CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, July 10th. Singular Research raised CalciMedica to a “moderate buy” rating in a report on Friday, June 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of CalciMedica in a report on Tuesday, August 13th.

Insider Transactions at CalciMedica

In other news, Director Robert N. Wilson bought 8,443 shares of the stock in a transaction on Thursday, June 27th. The stock was acquired at an average price of $3.23 per share, with a total value of $27,270.89. Following the acquisition, the director now directly owns 258,918 shares in the company, valued at $836,305.14. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 53.30% of the stock is owned by insiders.

Institutional Investors Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. BML Capital Management LLC raised its stake in CalciMedica, Inc. (NASDAQ:CALC) by 63.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 145,424 shares of the company’s stock after buying an additional 56,643 shares during the period. CalciMedica comprises about 0.3% of BML Capital Management LLC’s portfolio, making the stock its 29th biggest position. BML Capital Management LLC owned 2.56% of CalciMedica worth $416,000 as of its most recent filing with the Securities and Exchange Commission.

CalciMedica Stock Up 2.1 %

Shares of NASDAQ CALC traded up $0.09 during trading on Friday, reaching $4.19. The company had a trading volume of 10,836 shares, compared to its average volume of 28,587. The company’s fifty day moving average price is $4.54 and its 200-day moving average price is $4.73. CalciMedica has a 12 month low of $1.75 and a 12 month high of $8.38. The stock has a market cap of $45.01 million, a P/E ratio of -1.95 and a beta of 1.28.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.